Document:

Document

Exhibit 4.2 

OPEN TEXT CORPORATION
EMPLOYEE STOCK PURCHASE PLAN
As Amended September 14, 2020

Article 1 - Purpose 

This amended Employee Stock Purchase Plan (the “Plan”) is intended to encourage share ownership by all eligible employees of Open Text Corporation (the “Company”), a corporation governed by the laws of Canada, and each of its Participating Subsidiaries, so that they may participate in any future growth of the Company by acquiring or increasing their interest in common shares of the Company. The Plan is designed to encourage eligible employees to remain in the employ of the Company and its Participating Subsidiaries. The Plan is intended to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Code”).

Article 2 - Definitions

The term “Affiliate” means any entity, other than a Subsidiary, that (a) directly or indirectly, is controlled by, controls or is under common control with, the Company, or (b) any entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing.
The term “applicable law” means any applicable law, domestic or foreign, including without limitation, applicable securities legislation, together with all regulations, rules, policy statements, rulings, notices, orders or other instruments thereunder and the rules of each securities exchange or quotation system on which securities of the Company are listed and posted for trading.
The term “Average Market Price” on any date means (i) the weighted average trading price of the Common Shares on the trading day immediately preceding such day on the securities exchange or quotation system on which the greatest volume of trading of the Common Shares in that period has occurred, if the Common Shares are then traded on such securities exchange or quotation system; or (ii) the average of the closing bid and asked prices last quoted on the trading day immediately preceding such day by an established quotation service for over-the-counter securities, if the Common Shares are not traded on a national securities exchange or quotation system; or (iii) if the Common Shares are not publicly traded, the fair market value of the Common Shares on such date as determined by the Committee after taking into consideration all factors which it deems appropriate, including, without limitation, recent sale and offer prices of the Common Shares in private transactions negotiated at arm’s length.
The term “business day” means a day on which there is trading on the NASDAQ Global Select Market (“NASDAQ”) or the securities exchange, including the Toronto Stock Exchange (“TSX”), on which the greatest volume of trading of the Common Shares in the respective period has occurred; and if neither is applicable, a day that is not a Saturday, Sunday or statutory holiday in the Province of Ontario.
The term “Canadian Participant” means a Participant who is regularly employed by the Company, a Subsidiary or an Affiliate in Canada.
The term “Code” means the U.S. Internal Revenue Code of 1986, as amended. 

The term “Insider” means an insider of the Company or an Affiliate or Subsidiary as defined in the rules of the TSX Company Manual for the purpose of security-based compensation arrangements.
The term “Insider Trading Policy” refers to the insider trading policy of the Company, pursuant to which directors and certain officers and employees of the Company and Participating Subsidiaries are prohibited from trading in securities of the Company during regularly scheduled and additional periods referred to as “trading black-outs periods”.
The term “Offering” means an offer under the Plan of an option that may be exercised at the end of a Purchase Period as further described in Article 8. Unless otherwise specified by the Committee, each Offering under the Plan to the eligible employees of the Company or a Participating Subsidiary shall be deemed a separate Offering, even if the dates of the applicable Purchase Periods of each such Offering are identical, and the provisions of the Plan will separately apply to each Offering. 
The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the Code.
The term “Participant” means an individual who is eligible as determined in accordance with Article 4 to participate in the Plan and who has complied with the provisions of Article 9.
The term “Participating Subsidiary” shall mean any present or future Subsidiary or Affiliate that is designated from time to time by the Board to participate in the Plan.  The Board shall have the power to make such designation before or after the Plan is approved by the shareholders.
The term “securities exchange” means the NASDAQ or the TSX or, if the Common Shares are not then listed and posted for trading on the NASDAQ or the TSX, such other securities exchange on which such Common Shares are listed and posted for trading as may be selected for such purpose by the Committee.
The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of the Code.

Article 3 - Administration of the Plan

The Plan will be administered by the Compensation Committee (the “Committee”) of the Company’s board of directors (the “Board”). Acts by a majority of the Committee, or acts reduced to or approved in writing by a majority of the members of the Committee, shall be the valid acts of the Committee. For any period during which no such committee is in existence, “Committee” shall mean the Board and all authority and responsibility assigned to the Committee under the Plan shall be exercised, if at all, by the Board, and the term “Committee” wherever used herein shall be deemed to mean the Board. 
The Committee has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable (including, without limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees who are non-residents of Canada or employed outside of Canada); (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan; (iv) designate separate Offerings under the Plan; (v) decide all disputes arising in connection with the Plan; and (vi) otherwise supervise the administration of the Plan. All interpretations and decisions of the 

Committee shall be binding on all persons, including the Company and the Participants, unless otherwise determined by the Board. No member of the Board, the Committee or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder.

Article 4 -  Eligible Employees

All individuals classified as employees on the payroll records of the Company and each Participating Subsidiary are eligible to participate in any one or more of the Purchase Periods under the Plan, provided that as of the first business day of the applicable Purchase Period they are customarily employed by the Company or a Participating Subsidiary for more than twenty (20) hours a week, or any lesser number of hours per week established by the Committee (if required under applicable local law) for purposes of any separate Offering. Notwithstanding any other provision herein, individuals who are not classified as employees of the Company or a Participating Subsidiary for purposes of the Company’s or applicable Participating Subsidiary’s payroll system are not considered to be eligible employees of the Company or any Participating Subsidiary and shall not be eligible to participate in the Plan. Eligible employees who are Participants on the first business day of any Purchase Period shall receive their options as of such day.  Individuals who become Participants after any date on which options are granted under the Plan shall be granted options on the first day of the next succeeding Purchase Period on which options are granted to eligible employees under the Plan.  
In any event, no employee may be granted an option under the Plan if such employee, immediately after the option was granted, would be treated as owning shares possessing five percent or more of the total combined voting power or value of all classes of shares of the Company or of any Parent or Subsidiary.  For purposes of determining ownership under this paragraph, the rules of Section 424(d) of the Code shall apply, and shares of the Company or any Parent or Subsidiary which the employee may purchase under outstanding options shall be treated as shares owned by the employee.

Article 5 - Shares Subject to the Plan

The shares subject to the options under the Plan shall be made available from either authorized but unissued common shares in the capital of the Company (the “Common Shares”), or from Common Shares purchased on the open market or otherwise by the trustee of a trust upon the direction of the Committee, or by an agent or broker designated by an administrator of the Plan appointed by the Committee. The aggregate number of Common Shares that may be issued under the Plan is 8,000,000, subject to adjustment as provided in Article 14. If any option granted under the Plan shall expire or terminate for any reason without having been exercised in full or shall cease for any reason to be exercisable in whole or in part, the unpurchased Common Shares subject thereto shall again be available under the Plan.
The maximum number of Common Shares of the Company issued to Insiders within any one year period, or issuable to Insiders at any time, under all security based compensation arrangements, shall not exceed ten percent of the number of the then issued and outstanding Common Shares of the Company.

Article 6 - Purchase Period

Purchase periods during which payroll deductions will be accumulated under the Plan shall consist of the six month periods commencing on January 1 and July 1, and ending on June 30 and December 31 of each calendar year, provided that the Committee may establish different purchase periods, from time to time, in advance of their commencement having a duration of three months to twenty-four months (each, a “Purchase Period” and collectively, the “Purchase Periods”). Contributions under the Plan shall be made by way of payroll deductions in accordance with Article 10.

Article 7 - Grant of Share Options 

Twice a year, or as otherwise determined by the Committee, on the first business day of a Purchase Period, the Company will grant to each eligible employee who is then a Participant in the Plan an option exercisable on the last day of such Purchase Period (the “Purchase Date”), to purchase, at the Option Price hereinafter provided for, a maximum of 100,000 Common Shares in accordance with this Plan on the condition that such employee remains eligible to participate in the Plan throughout the remainder of such Purchase Period, or such other lesser maximum number of Common Shares as shall have been established by the Committee in advance of the Purchase Period; provided, however, that such option shall be subject to the limitations set forth below.
Each Participant’s option shall be exercisable only to the extent of such Participant’s accumulated payroll deductions on the Purchase Date. The option price will be 85 percent of the Average Market Price (as defined in Article 2) of the Common Shares on the Purchase Date, rounded up to the nearest cent (the “Option Price”).  If a Participant’s accumulated payroll deductions on the last day of the Purchase Period would enable a Participant to purchase more than the share limit provided under this Article 7, the excess of the amount of the accumulated payroll deductions over the aggregate Option Price of the Common Shares permitted to be purchased under the Plan shall be promptly refunded to the Participant by the Company, without interest. The foregoing limitation on the number of Common Shares subject to option and the Option Price shall be subject to adjustments as provided in Article 14.
No Participant under the Plan may be granted an option that permits the Participant’s rights to purchase Common Shares under the Plan, and any other Section 423(b) employee stock purchase plans of the Company and its Parent and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such shares (determined on the option grant date or dates) for each calendar year in which the option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code. If the Participant’s accumulated payroll deductions on the Purchase Date would otherwise enable the Participant to purchase Common Shares in excess of the Section 423(b)(8) limitation described in this paragraph, the excess of the amount of the accumulated payroll deductions over the aggregate Option Price of the Common Shares actually purchased shall be promptly refunded to the Participant by the Company, without interest.

Article 8 - Exercise of Option

Each eligible employee who continues to be a Participant in the Plan on the Purchase Date shall be deemed to have exercised his or her option on such date and shall be deemed to have purchased from the Company such number of whole Common Shares reserved for the purpose of the 

Plan as the Participant’s accumulated payroll deductions on such date will pay for at the Option Price, subject to the 100,000 Common Share limit of the option and the Section 423(b)(8) limitation described in Article 7. If the individual is not a Participant on the Purchase Date, then he or she shall not be entitled to exercise his or her option.  Only whole Common Shares may be purchased under the Plan. Unused payroll deductions remaining in a Participant’s account at the end of a Purchase Period by reason of the inability to purchase a fractional share shall be carried forward to the next Purchase Period.

Article 9 - Plan Enrollment

An eligible employee may elect to enter the Plan, at the discretion of the Committee, (i) through an electronic enrollment that provides required enrollment information requested by the Company, or (ii) by filling out, signing and delivering to the Company an authorization in a form specified by the Committee, in either case:
A.stating the percentage to be deducted regularly from the employee’s Compensation (or contributed by other means to the extent permitted by the Committee);

B.authorizing the purchase of Common Shares for the employee in each Purchase Period in accordance with the terms of the Plan; and

C.specifying the exact name or names in which Common Shares purchased for the employee are to be issued as provided under Article 13 hereof.

Such enrollment or authorization must be received by the Company at least ten days before the first day of the next succeeding Purchase Period and shall take effect only if the employee is an eligible employee on the first business day of such Purchase Period, unless otherwise required by applicable law.
Unless a Participant completes a new election under Article 11 or withdraws from the Plan or no longer meets the eligibility requirements in Article 4, the deductions and purchases under the enrollment or authorization on file for the Participant under the Plan will continue automatically from one Purchase Period to succeeding Purchase Periods as long as the Plan remains in effect.
The Company will accumulate and hold for each Participant’s account the amounts deducted from his or her pay. No interest will be paid on these amounts.
Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code or other applicable law.

Article 10 - Maximum Amount of Payroll Deductions

Each eligible employee may authorize payroll deductions in an amount (expressed as a whole percentage) not less than one percent and not more than fifteen percent of such employee’s Compensation (as defined below) for each pay period. An amount equal to the elected percentage of the Participant’s base salary plus any commissions and bonus, paid on a gross basis before any deduction for tax or other amounts (“Compensation”) shall be deducted on each regular payday falling within the Purchase Period.  All amounts will be calculated on the Participant’s gross Compensation, and deducted from a Participant’s net pay on an after-tax basis. The Company will 

maintain book accounts showing the amount of payroll deductions made on behalf of each Participant for each Purchase Period.

Article 11 - Change in Payroll Deductions

A Participant may elect to increase or decrease his or her rate of payroll deduction by submitting an election (which may be in electronic form), at any time during a Purchase Period, in accordance with, and if and to the extent permitted by, procedures established by the Company from time to time, which may, if permitted by the Company, include a decrease to zero percent; provided, however, that unless determined otherwise by the Committee, a decrease to zero percent shall be a deemed withdrawal from the Plan. Any such election is subject to compliance with the Company’s Insider Trading Policy and applicable trading black-out periods.
A Participant that stops payroll deductions in any Purchase Period in accordance with the foregoing or that withdraws from the Plan may not elect to participate further in the Plan until the next Purchase Period except with the written consent of the Company.

Article 12 - Withdrawal from the Plan

A Participant may withdraw from participation in the Plan (in whole but not in part) at any time, except, with respect to withdrawal from a Purchase Period, on the last day of the Purchase Period, in accordance with the procedures prescribed by the Committee by delivering a notice of withdrawal (which may be in electronic form) to the Company or a person designated by the Company. The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s withdrawal, the Company will promptly refund the amount of the Participant’s aggregate payroll deductions for that Purchase Period to him or her (after payment for any Common Shares purchased before the effective date of withdrawal), without interest. Partial withdrawals are not permitted. Any such withdrawal is subject to compliance with the Company’s Insider Trading Policy and applicable trading black-out periods.
Such an employee may not begin participation again during the remainder of the Purchase Period, but may enroll in a subsequent Purchase Period in accordance with Article 9. The employee’s re-entry into the Plan becomes effective at the beginning of such Purchase Period, provided that he or she is an eligible employee on the first business day of the Purchase Period.

Article 13 - Issuance of Common Shares to Custodial Accounts

The Common Shares purchased by Participants will be issued electronically by the Company’s transfer agent to a Participant’s custodial account as soon as practicable after each Purchase Date. Common Shares purchased under the Plan will be issued only in the name of the Participant or his or her nominee (or, if his or her authorization so designates, in the name of the Participant and another person of legal age as joint tenants with rights of survivorship or a nominee). The custodial account of Participants shall be maintained by a bank, broker-dealer or similar custodian that has agreed to hold such shares for the accounts of the respective Participants.  A Participant or his or her legal representative may withdraw Common Shares from the Participant’s custodial account at any time. Fees and expenses of the bank, broker-dealer or similar custodian shall be paid by the Company or allocated among the respective Participants in such manner as the Committee determines.

Article 14 - Adjustments 

Upon the happening of any of the following described events, a Participant’s rights under options granted under the Plan shall be adjusted as hereinafter provided.
In the event that the Common Shares shall be subdivided or consolidated into a greater or smaller number of shares or if, upon a reorganization, split-up, liquidation, recapitalization or the like of the Company, the Common Shares shall be exchanged for other securities of the Company, each Participant shall be entitled, subject to the conditions herein stated, to purchase such number of Common Shares or amount of other securities of the Company as were exchangeable for the number of Common Shares that such Participant would have been entitled to purchase except for such action, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, consolidated or exchange.
Upon the happening of any of the foregoing events, the class and aggregate number of Common Shares set forth in Article 5 hereof which are subject to options which have been or may be granted under the Plan and the limitations set forth in Articles 7 and 8 shall also be appropriately adjusted to reflect the events specified in the above paragraph.  Notwithstanding the foregoing, any adjustments made pursuant to the above paragraph shall be made only after the Committee, based on advice of counsel for the Company, determines whether such adjustments would constitute a “modification” (as that term is defined in Section 424 of the Code).  If the Committee determines that such adjustments would constitute a modification, or that such change will constitute a change requiring shareholder approval, it may refrain from making such adjustments.
If the Company is to be consolidated with or acquired by another entity in a merger, a sale of all or substantially all of the Company’s assets or otherwise (an “Acquisition”), the Committee or the board of directors of any entity assuming the obligations of the Company hereunder (the “Successor Board”) shall, with respect to options then outstanding under the Plan, either (i) make appropriate provision for the continuation of such options by arranging for the substitution on an equitable basis for the shares then subject to such options either (a) the consideration payable with respect to the outstanding Common Shares in connection with the Acquisition, (b) shares of the successor corporation, or a parent or subsidiary of such corporation, or (c) such other securities as the Successor Board deems appropriate, the fair market value of which shall not exceed the fair market value of the Common Shares subject to such options immediately preceding the Acquisition; or (ii) terminate each Participant’s options in exchange for a cash payment equal to the excess of (a) the fair market value on the date of the Acquisition, of the number of Common Shares that the Participant’s accumulated payroll deductions as of the date of the Acquisition could purchase, at an option price determined with reference only to the first business day of the applicable Purchase Period and subject to Code Section 423(b)(8) and fractional-share limitations on the amount of shares a Participant would be entitled to purchase, over (b) the result of multiplying such number of shares by such option price.
The Committee or Successor Board shall determine the adjustments to be made under this Article 14, and its determination shall be conclusive.

Article 15 - No Transfer or Assignment of Employee’s Rights 

An option granted under the Plan or a Participant’s rights under the Plan may not be pledged, assigned, encumbered or otherwise transferred for any reason, except by will or laws of descent and distribution, and are exercisable during the Participant’s lifetime only by the Participant.  Any attempt to pledge, assign, encumber or transfer an option or any rights hereunder will be deemed to be an election by the Participant to withdraw from the Plan in accordance with Article 12.

Article 16 - Designation of Beneficiary 

A Participant may file a written designation of a beneficiary who is to receive any Common Shares and cash, if any, from the Participant’s account under the Plan in the event of such Participant’s death subsequent to a Purchase Date on which the option is exercised but prior to delivery to him or her of such Common Shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant’s account under the Plan in the event of such Participant’s death prior to the exercise of an option. 
Such designation of beneficiary may be changed by the Participant (and his or her spouse, if any) at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant’s death, the Company shall deliver such Common Shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such Common Shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

Article 17 - Termination of Employee’s Rights 

Whenever a Participant ceases to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death or for any other reason before the Purchase Date for any Purchase Period, the option will automatically be terminated  on the date that the Participant ceases to be an eligible employee except in the case of involuntary termination, in which case the option will automatically be terminated on the date that notice of termination of employment is delivered to the eligible employee, without regard to any notice, pay in lieu of notice, severance pay or similar compensation to which the eligible employee may be entitled, except as otherwise expressly required by applicable employment or labour standards legislation, and the Participant shall have no claim for damages in lieu or in respect of the termination of such option. In such event, the Company shall promptly refund the entire balance of the Participant’s payroll deduction account, without interest, to such Participant or, in the case of such Participant’s death, to his or her designated beneficiary, as if such Participant had withdrawn from the Plan in accordance with Article 12. Notwithstanding the foregoing, eligible employment shall be treated as continuing intact while a Participant is on sick leave or other bona fide leave of absence, for up to 90 days, or for so long as the Participant’s right to re-employment is guaranteed either by statute or by contract, if longer than 90 days.
This Plan does not, directly or indirectly, create any right for the benefit of any employee or class of employees to preferentially purchase any Common Shares under the Plan, or create in any 

employee or class of employees any right with respect to continuation of employment by the Company, and it shall not be deemed to interfere in any way with the Company’s right to terminate, or otherwise modify, an employee’s employment at any time.

Article 18 - Special Rules

Notwithstanding anything herein to the contrary, the Committee may adopt special rules applicable to the employees of a particular Participating Subsidiary, whenever the Committee determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Participating Subsidiary has employees; provided that such rules are consistent with the requirements of Section 423(b) of the Code. Any special rules established pursuant to this Article 18 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan.

Article 19 - Interest

No interest will accrue on the accumulated payroll deductions or other contributions permitted by the Committee of a Participant, except as may be required by applicable local law, as determined by the Company, and if so required by the laws of a particular jurisdiction, shall apply to all Participants in the relevant Offering under the Plan, except to the extent otherwise permitted by applicable law.

Article 20 - Termination and Amendments to Plan 

The Plan may be terminated at any time by the Board but such termination shall not affect options then outstanding under the Plan. It will terminate in any case when all or substantially all of the unissued Common Shares reserved for the purposes of the Plan have been purchased. If at any time Common Shares reserved for the purpose of the Plan remain available for purchase but not in sufficient number to satisfy all then unfilled purchase rights, the available Common Shares shall be allocated pro rata among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Shares, and the Plan shall terminate. Upon such termination or any other termination of the Plan, all payroll deductions not used to purchase Common Shares will be refunded, without interest.
The Committee or the Board may from time to time adopt amendments to the Plan provided that, without the approval of the shareholders of the Company, no amendment may (i) increase the number of Common Shares that may be issued under the Plan; (ii) provide for or increase the amount of any cash contribution that may be made by the Company to the purchase of Common Shares by any employee participating in the Plan; (iii) increase the maximum percentage of base salary during any pay period or the maximum dollar amount in any one calendar year that any eligible Participant may direct be contributed, pursuant to the Plan, towards the purchase of Common Shares on his or her behalf through payroll deductions; (iv) increase the Option Price discount as further described in Article 7; (v) increase the limits on the total number of Common Shares that may be acquired by any one individual under the Plan or any one Insider of the Company and the Insider’s associates; (vi) change the eligible Participants in a manner that would have the potential for broadening or increasing the Insider participation in the Plan; or (vii) increase the limit on the total number of Common Shares that may be acquired by Insiders of the Company or acquired by Insiders within a one-year period.

In addition, any modification or amendment to the Plan will be subject to the prior approval of the TSX to the extent that the Common Shares are listed on the TSX at the time of such proposed termination, modification or amendment.

Article 21 - Limits on Sale of Shares Purchased under the Plan

The Plan is intended to provide Common Shares for investment and not for resale.  The Company does not, however, intend to restrict or influence any employee in the conduct of his or her own affairs.  An employee may, therefore, sell Common Shares purchased under the Plan at any time the employee chooses, subject to compliance with any applicable federal, state and provincial securities laws and regulations; subject to any restrictions imposed under Article 25 to ensure that tax withholding obligations are satisfied; subject to compliance with the terms of the Company’s Insider Trading Policy; and subject to compliance with any conditions imposed by the Committee or the Board under the Plan with respect to any subsequent purchases made by Participants under the Plan. THE EMPLOYEE ASSUMES THE RISK OF ANY MARKET FLUCTUATIONS IN THE PRICE OF THE COMMON SHARES.

Article 22 - Optionees Not Shareholders
 
Neither the granting of an option to a Participant nor the deductions from his or her pay shall constitute such Participant a shareholder of the shares covered by an option under the Plan until such shares have been purchased by and issued to him or her. Notwithstanding the foregoing, the Company shall deliver to each Participant under this Plan who does not otherwise receive such materials (a) a copy of the Company’s annual financial statements, together with management’s discussion and analysis of financial condition and results of operations for the fiscal year, and (b) a copy of all reports, proxy statements and other communications distributed to the Company’s security holders generally.

Article 23 - Application of Funds

All funds received or held by the Company under the Plan may be combined with other corporate funds, and may be used for general corporate purposes.

Article 24 - Notice to Company of Disqualifying Disposition

By electing to participate in the Plan, each United States of America resident agrees to notify the Company in writing immediately after the Participant transfers Common Shares acquired under the Plan, if such transfer occurs within two years after the first business day of the Purchase Period in which such Common Shares were acquired.  Each Participant further agrees to provide any information about such a transfer as may be requested by the Company or any Subsidiary in order to assist it in complying with the tax laws.  
  
Article 25 - Withholding of Additional Taxes 

By electing to participate in the Plan, each Participant acknowledges that the Company and its Participating Subsidiaries are required to withhold taxes with respect to the amounts deducted from the Participant’s Compensation and accumulated for the benefit of the Participant under the Plan, and each Participant agrees that the Company and its Participating Subsidiaries may deduct 

additional amounts from the Participant’s Compensation, when amounts are added to the Participant’s account, used to purchase Common Shares or refunded, in order to satisfy such withholding obligations.  Each Participant further acknowledges that when Common Shares are purchased under the Plan the Company and its Participating Subsidiaries may be required to withhold taxes with respect to all or a portion of the difference between the fair market value of the Common Shares purchased and their purchase price and any other taxable benefit arising from participation in the Plan, and each Participant agrees that such taxes may be withheld from Compensation otherwise payable to such Participant.  It is intended that tax withholding will be accomplished in such a manner that the full amount of payroll deductions elected by the Participant under Article 9 will be used to purchase the Common Shares.  However, if amounts sufficient to satisfy applicable tax withholding obligations have not been withheld from Compensation otherwise payable to any Participant, then, notwithstanding any other provision of the Plan, the Company may withhold such taxes from the Participant’s accumulated payroll deductions and apply the net amount to the purchase of Common Shares, unless the Participant pays to the Company, prior to the Purchase Date, an amount sufficient to satisfy such withholding obligations. Each Participant further acknowledges that the Company and its Participating Subsidiaries may be required to withhold taxes in connection with the disposition of Common Shares acquired under the Plan and agrees that the Company or any Participating Subsidiary may take whatever action it considers appropriate to satisfy such withholding requirements, including deducting from Compensation otherwise payable to such Participant an amount sufficient to satisfy such withholding requirements or conditioning any disposition of Common Shares by the Participant upon the payment to the Company or such Participating Subsidiary of an amount sufficient to satisfy such withholding requirements. For purposes of this Article 25, “taxes” include all remuneration-related deductions, withholdings and contributions required by any governmental authority.

Article 26 - Governmental Regulations 

The Company’s obligation to sell and deliver Common Shares under the Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares. Common Shares shall not be issued with respect to an option granted under the Plan unless the exercise of such option and the issuance and delivery of the shares of Common Shares pursuant thereto shall comply with all applicable laws and regulations and the requirements of any stock exchange upon which the shares may then be listed.

Article 27 - Governing Law

The validity and construction of the Plan shall be governed by the laws of Ontario, without giving effect to the principles of conflicts of law thereof.

Article 28 - Approval of the Board and Shareholders of the Company

This Plan shall be effective as of the date it is approved by the holders of a majority of the Common Shares of the Company present or represented by proxy at the annual meeting of the shareholders of the Company, held after the date on which the Plan is adopted by the Board, and in a manner that complies with Section 423(b)(2) of the Code and applicable Canadian law. Notwithstanding the foregoing, the terms of this Plan shall not apply until Purchase Periods commencing on or after January 1, 2016, unless otherwise determined by the Committee.

Article 29 - Miscellaneous

All references to currency herein are to U.S. funds unless otherwise indicated.Exhibit 10.25

 

DISTRIBUTION AGREEMENT

Proprietary and Confidential

 

THIS DISTRIBUTION AGREEMENT (“Agreement”)
is made effective as of the 21 day of April, 2020 (“Effective Date”) and is entered into by and between;

 

G Medical Innovations, Ltd. (“G MEDICAL”),
Company No._______________, a limited liability company, having its principal place of business at, 5, Oppenheimer St. Rehovot,
7670105, Israel, and

 

Home
Service Solutions Pty Ltd (“HSS”),
Company No. 616 760 171, a limited liability company, having its principal place of business at, L 2, 22 Mount Street, Perth,
Western Australia. (“Distributor”).

 

G MEDICAL and Distributor are hereinafter sometimes referred
to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, G MEDICAL is in the business
of developing and offering mobile health and e-health solutions and products;

 

WHEREAS, Distributor desires to purchase
products from G MEDICAL from time to time, for distribution, sale and resale to end user consumers and entities located in the
Territory (as defined below); and

 

WHEREAS, the Parties desire to enter
into a distributor relationship, pursuant to the governing terms and mutual promises which are set out in this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual promises contained herein and intending to be legally bound, G MEDICAL and Distributor agree as follows:

 

1. PRODUCT DISTRIBUTION
RIGHTS

 

1.1 Purpose of this Agreement. The
purpose of this Agreement is to set forth the respective duties and obligations of G MEDICAL and Distributor with respect to the
distribution of products and services offered by G MEDICAL from time to time as described in Exhibit A (“Products”).

 

1.2 Appointment/Obligation
of Distributor. Subject to the terms and conditions of this Agreement, G MEDICAL hereby appoints Distributor for the term of
this Agreement as a non-exclusive distributor of the Products within the geographic area and restrictions described in Exhibit
B (the “Territory”). Distributor accepts this appointment upon the terms and conditions herein and agrees
that for the term of this Agreement Distributor will: (a) use its best commercial efforts to develop business in, to promote
the sale of, and to sell the Products in the Territory; (b) maintain a representative and adequate inventory of Products and include
a representative listing of Products in any catalog Distributor may issue for use or distribution in the Territory; (c) provide
on a periodic basis such information and reports of inventories, sales and other pertinent information as G MEDICAL in the reasonable
exercise of its judgment may from time to time request; (d) Keep an updated list of all end user consumers and entities (“End
Users”) (including End User’s name, address and contact details), which have purchased the Products and shall supply
a copy of such list from time to time promptly following G MEDICAL’s written request; and (e) take reasonable, good faith
action in communicating and carrying out advertising and promotional programs and services within the Territory.

 

1.3 Distributor
shall, in addition to the above: (a) bear all responsibility for and risk of sales to End Users, invoicing its End Users, extending
credit to its End Users, collection of sales tax, collection of receivables from its End Users, distribution costs and the like;
(b) conduct the business pursuant to this Agreement in an ethical, orderly and businesslike manner and strictly in compliance with
the provisions hereof; (c) not make any representations or give any warranties with regard to the Products, except as provided
by G Medical; (d) not, during the term of this Agreement and for a period of twelve (12) months following the expiration or termination
of this Agreement for any reason - manufacture, market, distribute or sell, or gain a financial interest in or otherwise be involved,
either directly or indirectly, in any business which is involved in the development, marketing or sale, of goods which are identical
or similar to the Products, or any other services which relate to the Products, within the Territory, other than the Products under
this Agreement; (e) not, by act or omission, harm or damage the goodwill of G MEDICAL and/or its business; (f) obtain and maintain
throughout the term of this Agreement, all permits, licenses and authorizations that may be necessary under any applicable
law, agreement or otherwise, for the performance of this Agreement; and (g) inform G MEDICAL promptly of any claim by an End User
and the way it was handled by the Distributor.

 

     
 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

1.4 Products. The Products available
for distribution and resale within the Territory shall be as set forth on Exhibit A, which may be amended or modified from
time to time by G MEDICAL.

 

1.5 Permitted Distribution and Restrictions.
Distributor may only resell and distribute the Products in the Territory and in no other geographic region. Distributor shall not
directly or indirectly (i) engage in the promotion of the Products outside the Territory; (ii) transship, convey, gift, sell or
otherwise transfer the Products outside the Territory, and/or (iii) sell Products to any person or entity that intends to sell
the Products outside the Territory; unless explicitly authorized in advance by G MEDICAL in writing. Exhibit B may be amended
by G MEDICAL from time to time upon providing thirty (30) days prior written notice to Distributor.

 

1.6 Non-Exclusivity.

 

The appointment of
the Distributor hereunder is on a non-exclusive basis and G MEDICAL may enter into similar and/or competing arrangements with other
parties.

 

Without derogating
from the above, Distributor shall, during the term of this Agreement, immediately advise G MEDICAL, in writing, should it encounter
any potential or actual conflict with G MEDICAL’s interests hereunder.

 

2. TERM AND TERMINATION

 

2.1 Term. The initial term of this
Agreement is one (1) year from the Effective Date, unless terminated earlier pursuant to the terms and conditions set forth in
this Agreement. Thereafter the Agreement will automatically renew for successive one (1) year terms, unless either Party provides
written notice of its intent not to renew this Agreement at least thirty (30) days prior to the applicable anniversary date.

 

2.2 Termination. This Agreement
shall terminate upon thirty (30) days advance written notice by G MEDICAL. Notwithstanding the above, G MEDICAL may terminate this
Agreement immediately if the Distributor is in breach of any of the terms and conditions in this Agreement or in the event Distributor
ceases to conduct business in the normal course, becomes insolvent, makes a general assignment for the benefit of creditors, suffers
or permits the appointment of a receiver for its business or assets, or avails itself of or becomes subject to any proceeding under
any applicable bankruptcy or insolvency law.

 

2.3 Effect of Termination; Survival.

 

Upon expiration or termination for any reason of this Agreement,
the following will apply:

 

(a) The appointment of Distributor as a
distributor of G MEDICAL under Section 1.2 above shall terminate on the effective date of termination;

 

(b) The Distributor shall immediately (i)
cease to conduct the business pursuant to this Agreement and to represent itself as a Distributor of G MEDICAL; (ii) cease to make
use of G MEDICAL’s Intellectual Property, and shall immediately sign all the necessary documents for cancellation of the
Marks license as recorded in the Territory; (iii) cease to use, and shall deliver to G MEDICAL, any unused sales literature and
other written information and materials supplied by G MEDICAL pursuant to this Agreement or which contain G MEDICAL’s Marks
and any other of G MEDICAL’s Intellectual Property Rights; and (iv) return to G MEDICAL any G MEDICAL Confidential Information
disclosed to it in writing or in any other tangible form.

 

    		Page 2 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

(c) Any amounts owed by the Distributor
pursuant to this Agreement shall become immediately due and payable. The Distributor shall promptly make any and all outstanding
payments to G MEDICAL within no more than seven (7) days from the expiration or termination date;

 

(d) G MEDICAL shall have no obligation
to compensate the Distributor for the expiration or termination of this Agreement, including but not limited to, any costs, fees
and expenses which the Distributor has incurred in connection with this Agreement and/or the conducting the business pursuant thereto,
and the Distributor hereby waives any and all rights to damages or any other remedies that the Distributor might otherwise have
upon any expiration or termination of this Agreement;

 

(e) Termination shall not derogate from
rights and obligations accrued prior to the effective date of termination, and shall not relieve Distributor from any payment obligations
hereunder that remain unpaid, or limit either Party from pursuing other available remedies, provided that G MEDICAL’s total
liability shall be limited as set out in Section 16.5 above; and

 

The provisions of Sections 4, 8, 9, 12 through and including
16 hereto, shall survive the expiration or termination of this Agreement for any reason, together with such other provisions necessary
to give effect to such provisions.

 

3. ROLLING FORECAST
AND PURCHASE ORDERS

 

3.1 Forecasts.
Distributor will deliver to G MEDICAL a thirty-six (36) month rolling forecast per model on a monthly basis in writing based
on Distributor’s anticipated requirements for Products (each a “Forecast”). The first Forecast will be
submitted thirty (30) days after state regulatory approval. The first twelve (12) months of the Forecast shall be binding,
and the remainder of the Forecast shall be non-binding. The Forecast shall specify the quantity of each type of Products that the
Distributor expects to purchase on a month-to-month basis during the Forecast period.

 

3.2 Purchase Orders. All purchases
of Products shall be initiated by Distributor’s issuance of a purchase order sent in writing or, if available, via electronic
data interchange to G MEDICAL (“Purchase Order(s)”). Distributor’s legal entity name, which shall be identical
to the signing party of this Agreement shall be listed under the “bill to” name on the Purchase Order for billing purposes.
Distributor shall issue the Purchase Orders Not later than sixteen (16) weeks prior to the requested ship date. Such orders
shall identify the quantity and type of Products desired and the requested ship dates. G MEDICAL shall use reasonable efforts to
notify Distributor of the acceptance or rejection of each Purchase Order within seven (7) days of its receipt. Upon Purchase
Order acceptance, G MEDICAL shall provide Distributor with a committed ship date within seven (7) days. The individual contracts
for the sale of Products formed by Distributor’s submission of Purchase Orders to G MEDICAL pursuant to the terms and conditions
hereof shall automatically incorporate, to the extent applicable, the terms and conditions of this Agreement, shall be subject
only to those terms and conditions contemplated by this Agreement and shall not be subject to any conflicting or additional terms
included in any documents exchanged in connection therewith. Other than as expressly provided for herein, the terms and conditions
on any Purchase Order issued by Distributor are null and void and shall have no force or effect whatsoever.

 

3.3 Purchase Order Processing. G
MEDICAL reserves the right to reject any Purchase Order in whole or in part, and delivery of part of an order shall not obligate
G MEDICAL to make further deliveries. A Purchase Order shall be considered accepted by G MEDICAL only by one of the following means:
(a) issuance of an acknowledgement in writing by G MEDICAL’s authorized representative; or (b) shipment of Products ordered
to the extent such Products are shipped.

 

3.4 Purchase Order Cancellation.
All cancellation of Purchase Orders by Distributor shall be in writing and are available only for Purchase Orders not yet shipped.
If Distributor cancels a Purchase Order, which has been accepted by G MEDICAL, Distributor shall reimburse G MEDICAL at its first
demand for any cost incident to such Purchase Order incurred by G MEDICAL prior to the time it was informed of the cancellation.

 

3.5 Field Replacement Units. G MEDICAL
shall provide Distributor free of charge an extra supply of Products (handset and battery only or wireless device only) equal to
Five percent (5%) of all Distributor Purchase Orders (“FRU”) which Distributor shall use for replacement purpose
of any units sold by Distributor are returned.

 

    		Page 3 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Any replaced Unit shall be returned to
G Medical for investigation and analysis of the problem led to the Unit replacement. Distributor shall maintain a monthly RMA shipment
of replaced product. Notwithstanding anything in this Agreement to the contrary, except for FRU, G MEDICAL shall not be obligated
to provide any additional replacement or other “free” units to Distributor or its customers, even if any such returned
Product is under warranty.

 

4. PRICING TERMS

 

Pricing of Products to be purchased by
Distributor shall be at the prices as determined by the G MEDICAL from time to time. G MEDICAL reserves the right, in its sole
discretion, to change prices or discounts applicable to the Products. G MEDICAL shall give written notice to Distributor of any
price change at least thirty (30) days prior to applying such price change.

 

Subject to applicable law, G MEDICAL shall
have the right, but not the obligation, to determine pricing at which Distributor offers Products to its customers, provided, however,
that if G MEDICAL shall exercise this right, it shall account for Distributor to make a reasonable profit from its sales based
on market profit.

 

Neither Distributor and/or any third party
shall be entitled to any payment whatsoever (including, without limitation, any reimbursement of expenses) from G MEDICAL for any
activities of Distributor performed in accordance with this Agreement, which shall be deemed to be made at Distributor’s
own risk, liability and expense.

 

5. DELIVERY AND RISK OF LOSS; OWNERSHIP

 

All deliveries of Products sold by G MEDICAL
to Distributor pursuant to this Agreement shall be made FCA (Incoterms 2010). Risk of loss of Products shall pass from G MEDICAL
to Distributor once the Products are picked up by the Distributor at the loading area in G Medical distribution center in
Israel and/or in the European Union (the “Delivery Point”). Distributor shall be responsible for arranging all
transportation of Products, but if requested by Distributor, G MEDICAL shall, at Distributor’s sole expense, assist Distributor
in making such arrangements. Distributor shall also procure, at its own expense, insurance for the transportation of the Products,
and such insurance shall be of a kind and on terms current at the port of shipment. Distributor shall pay any and all charges,
including port, customs and forwarding fees if applicable and any and all sales tax, incurred with respect to the Products following
their Delivery to the Delivery Point.

 

All losses and damages to the Products
occurring prior the arrival of the Products to the Delivery Point shall be G MEDICAL’s liability, and all losses and damages
to the Products occurring after such point shall be Distributor’s liability.

 

Without limitation to the above, the transfer
of ownership to the applicable Products shall be effective only after receipt by G MEDICAL of full payment therefor.

 

6. PRODUCT PACKAGING

 

G MEDICAL shall, at its expense, pack all
Products in accordance with G MEDICAL’s standard packing procedure, which shall be suitable to permit shipment of the Products
to the Territory; provided, however, that if Distributor requests a modification of those procedures, G MEDICAL shall make the
requested modification and Distributor shall bear any and all expenses incurred by G MEDICAL in complying with such modified procedures
which are in excess of the expenses which G MEDICAL would have incurred in following its standard procedures.

 

7. INSPECTION, ACCEPTANCE AND WARRANTY

 

7.1 Promptly
upon the receipt of a shipment of Products, Distributor shall examine the shipment to determine whether any item or items included
in the shipment are in short supply, defective or damaged. Within seven (7) days of receipt of the shipment, Distributor shall
notify G MEDICAL in writing of any shortages, defects or damage which Distributor claims existed at the time of delivery. The shipment
shall be deemed accepted as is for any portion (if Distributor notifies G MEDICAL of a problem with a portion of the shipment)
or the entire shipment, in each case if Distributor fails to timely notify G MEDICAL in writing of any concern or issue.
Within fifteen (15) days after the receipt of such notice, G MEDICAL will investigate the claim of shortages, defects or damage,
inform Distributor of its findings, and thereafter deliver to Distributor Products to replace any which G MEDICAL determines, in
its sole discretion, were in short supply, defective or damaged at the time of delivery, and rectify as G MEDICAL deems appropriate
in its sole discretion if G MEDICAL determines that a shipment as delivered was inadequate.

 

    		Page 4 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

7.2 G Medical shall replace at its expense
any Products sold to End Users found defective by Distributor during a warranty period of 12 months and returned to Distributor
for repair. Return of the replacement Products to Distributor’s original destination shall be at the expense of G Medical,
unless G Medical determines that the Product is not defective within the terms of the warranty, in which event Distributor shall
pay G Medical all costs of handling, transportation and labor at G Medical’s then prevailing rates.

 

		7.3	The distributor will maintain records of all complaints, oral or written, received from customers.
Such complaints will be notified to the manufacturer for investigation and handling within 24 hours and will be handled by the
distributor within 5 working days (in order to complete the handling process).
	 	 	 

		7.4	The distributor will maintain records of the distribution of medical devices to allow traceability
and allow these records to be available for inspection: Supplied product, serial number of the product (if applicable) name and
address of the customer, date of shipment, quantity shipped. The records shall be retained for at least seven years back; this
is necessary for quick and effective retrieval of distribution records in the event that the product is subject to Recall and/
Advisory Notice.
	 	 	 

		7.5	The distributor undertakes to store the product according to the environmental conditions specified
by the manufacturer (applicable to the patch).
	 	 	 

		7.6	The distributor will not perform any repackaging or relabeling for the product unless authorized
to do so in writing by the manufacturer.

 

7.7 Limitation on Warranties. Warranties
and Distributor’s remedies hereunder are solely for the benefit of Distributor and shall not be extended to any person whatsoever,
it being understood that the warranty to Distributor hereunder shall survive the sale or transfer of the Products. This warranty
shall not apply to any Product that (a) has been damaged by misuse, accident, neglect, or from any other cause beyond G Medical’s
reasonable control, including force majeure, and without G Medical’s fault or omission or negligence or the fault or negligence
or omission of G Medical; or (b) has been used in a manner not in accordance with the instructions supplied by G Medical.

 

7.8 THE WARRANTIES
PROVIDED IN THIS SECTION 7 CONSTITUTE G MEDICAL’S SOLE AND EXCLUSIVE LIABILITY FOR DEFECTIVE OR NONCONFORMING PRODUCT AND
SHALL CONSTITUTE DISTRIBUTOR’S SOLE AND EXCLUSIVE REMEDY FOR DEFECTIVE OR NONCONFORMING PRODUCT. THESE WARRANTIES ARE IN
LIEU OF ALL OTHER WARRANTIES EXPRESS OR IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, AND ARE IN LIEU OF ALL OBLIGATIONS OR LIABILITIES ON THE PART OF G MEDICAL FOR DAMAGES.

 

8. INVOICING AND PAYMENT

 

8.1 Prior to the delivery and/or acceptance
of Products, G MEDICAL may submit to Distributor G MEDICAL’s invoice for those Products. All payments shall be made in United
States Dollars (USD). All payments by Distributor must be made by wire transfer to G MEDICAL’s bank account unless there
is a letter of credit in which case the Distributor’s bank shall make payment. Distributor shall complete any G MEDICAL provided
credit application and financial statements, if requested by G MEDICAL. Payment shall be made by option (a) or (b) set
forth below:

 

(a)
For each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall deliver to G MEDICAL, as collateral
for the full and faithful performance by Distributor of all of its obligations under this Agreement, an irrevocable and unconditional
negotiable letter of credit, (the “Letter of Credit”) in the amount of the Purchase Order, payable at sight, from a
reputable bank acceptable to G MEDICAL. The Letter of Credit must be issued and confirmed seventy five (75) days prior to
the shipment date. In addition to the foregoing, the form and terms of the Letter of Credit (and the bank issuing the same) shall
be acceptable to G MEDICAL, in G MEDICAL’s sole discretion, and shall provide, among other things, that such Letter of Credit
shall be irrevocable, unconditional, and payable at sight; or

 

    		Page 5 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

(b) For the initial year of the
term, for each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall (i) wire thirty (30%)
of the total Purchase Order amount seventy five (75) days before shipment; and (ii) wire the remaining seventy percent
(70%) of the total Purchase Order amount of the Product ten (10) days before shipment. For each year of the term following
the initial year of the term, for each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall
(i) wire twenty percent (20%) of the total Purchase Order amount seventy five (75) days before shipment; and (ii)
wire the remaining eighty percent (80%) of the total Purchase Order amount of the Product ten (10) days before shipment

 

8.2 The payment terms allowed by G MEDICAL
may be subject to change based upon the financial condition of Distributor.

 

8.3 Distributor will be responsible for
obtaining all governmental and other approvals and complying with all formalities needed to effectuate any and all payments to
G MEDICAL as provided herein.

 

8.4 Distributor shall not be entitled to
withhold or delay any payment due to G MEDICAL hereunder, and shall not set off or deduct therefrom any amounts whatsoever.

 

8.5 All fees due to G MEDICAL hereunder
are net and are exclusive of all current and future taxes, including without limitation, sales, use, value-added, withholding or
other taxes, customs duties or levies on transactions made under this Agreement, all of which (except for taxes on the income of
G Medical) shall be borne by the Distributor.

 

9. ADVERTISING AND
TRADEMARK USE

 

9.1 Use
and Ownership of Marks. Distributor recognizes and acknowledges G MEDICAL’s ownership and title to its respective trademarks,
service marks, corporate slogans or logos and trade names whether or not registered (“Marks”). Distributor shall
use the Marks solely to identify the Products for purposes of Distributor’s performance under this Agreement . Distributor
may not use G MEDICAL the Marks in advertising, promotion, and publicity of the Products without the express written consent of
G MEDICAL. All permitted uses of the Marks shall be deemed to be a license thereof by G MEDICAL upon the provisions specified in
Section 1.2 above, and Distributor shall not acquire any rights, title, or interest in the Marks nor will it act to impair the
rights of G MEDICAL in such Marks, except for such rights of usage as may be permitted by this Section 9.1. Distributor
shall not adopt, use or register any names or symbols that are identical, or confusingly similar, to the Marks. Furthermore, the
Distributor shall not, directly or indirectly, at any time and in any jurisdiction, (i) use any of the Marks for any other purpose
except for the marketing of the Products as expressly allowed hereunder, (ii) attempt to misappropriate, circumvent or violate
any of G MEDICAL’s Intellectual Property, or other interests in the Products, (iii) dilute, damage or endanger the distinctiveness
of a Marks or depreciate the value attached thereto, nor (iv) modify, translate, or prepare derivative works based on the Marks.
The Distributor shall provide G MEDICAL, at G MEDICAL’s expense, with any assistance it may require in connection with the
registration of the Marks and the Marks license granted hereunder in the Territory. The Distributor hereby irrevocably designates
and appoints G MEDICAL as the Distributor’s agent and attorney-in-fact, at G MEDICAL’s sole discretion - to act for
and on the Distributor’s behalf and instead of the Distributor, to execute and file any such documents and to do all other
lawfully permitted acts to further the purposes of registration of the Marks and the Marks license granted hereunder in the Territory,
with the same legal force and effect as if executed by the Distributor.

 

9.2 Advertisements
Guidelines. Distributor shall submit examples of all proposed advertisements and other promotional materials for the Products
to G MEDICAL for inspection and Distributor shall not use any such advertisements or promotional materials without having received
the prior written consent of G MEDICAL to do so. The Distributor shall singly meet and bear all costs related to advertising and
marketing. However, G MEDICAL, in its sole discretion, may from time to time determine the nature or extent of its support
(if any) towards the marketing or advertising costs of the Distributor.

 

    		Page 6 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

9.3 Distributor acknowledges and agrees
that G MEDICAL shall have the right to (a) engage in quality control activities designed to protect G MEDICAL’s legal ownership
rights in its Marks and (b) engage in activities designed to ensure that Distributor is conducting its resale activities and other
operations in full compliance with this Agreement.

 

10. DISTRIBUTOR SALES AND STORAGE FACILITIES

 

Distributor shall, at its expense, at all
times store and maintain its inventory of Products in accordance with current, applicable instructions issued by G MEDICAL from
time to time. Distributor shall, at its expense, deliver one copy of G MEDICAL’s current, applicable operation and maintenance
manual to each End User at the time of sale and, at that time, Distributor shall, at its expense, fully explain and demonstrate
to the End User the proper method of operating and maintaining the Products. Distributor shall mail to G MEDICAL, during the term
of this Agreement, prompt written notice of the address of each location at which Products are stored, and the address of each
facility established by Distributor to sell the Products. G MEDICAL may, through its designated agent, inspect all such locations
and facilities and the operations conducted therein at any time during normal business hours.

 

11. TRAINING OF DISTRIBUTOR

 

As promptly as practicable after execution
of the Agreement, G MEDICAL shall transmit to Distributor information, materials, manuals and other technical documents deemed
necessary and appropriate by G MEDICAL to enable Distributor to perform its obligations under this Agreement. Throughout the term
of this Agreement, G MEDICAL shall continue to give Distributor such technical assistance as Distributor may reasonably request.
Distributor shall reimburse G MEDICAL for all out-of-pocket expenses incurred by G MEDICAL in providing technical assistance.

 

12. RELATIONSHIP OF PARTIES

 

12.1 Distributor is an independent contractor
and is not the legal representative, employee, partner, franchisee or agent of G MEDICAL for any purpose and shall have no right
or authority (except as expressly provided in this Agreement) to incur, assume or create in writing or otherwise, any obligation
of G MEDICAL.

 

12.2 Distributor shall, at its own expense,
during the term of this Agreement and any extension thereof, maintain full insurance under any Workmen’s Compensation Laws
effective in the Territory covering all persons employed by and working for it in connection with the performance of this Agreement,
and upon request shall furnish G MEDICAL with satisfactory evidence of the maintenance of such insurance.

 

12.3 Distributor will be solely responsible
for payment of all compensation owed to its employees, as well as employment-related taxes. Distributor accepts exclusive liability
for all contributions and payroll taxes required under the laws of the Territory or other payments under any laws of similar character
in any applicable jurisdiction as to all persons employed by and working for it. There shall be no employer-employee relationship
between the Parties and/ or the Parties’ employees.

 

12.4 Nothing contained in this Agreement
shall be deemed to create any partnership or joint venture relationship between the Parties.

 

13. REPRESENTATIONS AND WARRANTIES

 

13.1 Mutual Representations and Warranties.
Each Party hereby represents and warrants that:

 

		(a)	It has all requisite corporate power and authority to execute, deliver, and perform its obligations
under this Agreement;
	 	 	 

		(b)	Its signing of, and agreement to, this Agreement have been duly authorized by all requisite corporate
actions;
	 	 	 

		(c)	This Agreement is a valid and legally binding obligation thereon, enforceable against it in accordance
with its terms; and

 

    		Page 7 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

		(d)	Nothing contained in this Agreement or the performance thereof shall place the relevant Party in breach
or default of any obligation or other agreement, law or regulation by which it is bound or to which it is subject, or requires
the consent of any person or entity.

 

13.2 Distributor’s Representations.
In addition to and without derogating from the provisions of Section 13.1 above, Distributor hereby represents, warrants and covenants
that:

 

		(a)	It shall perform its obligations hereunder in full compliance with all applicable laws and regulations.
Such laws, regulations shall include, without limitation, tender and bidding laws, anti-corruption and anti-unfair competition
laws and regulations. The Distributor hereby acknowledges that it is fully aware of all the above-mentioned laws and regulations
and any possible violation of such laws and regulations by the Distributor, shall be the sole responsibility of the Distributor.
The Distributor shall indemnify and hold the G MEDICAL harmless from any and all loss or damage sustained because of the Distributor’s
non-compliance with any applicable laws and regulations;

 

		(b)	It has the required experience, expertise, personnel, facilities and resources in order to perform
all of Distributor’s obligations under this Agreement. Distributor’s personnel involved in performing its obligations
hereunder shall have sufficient skill, knowledge, and training to perform such services and carry out their assignments hereunder
and shall perform their tasks in a professional and workmanlike manner, consistent with the performance standards set out in this
Agreement, and at least in accordance with generally accepted industry standards;

 

		(c)	no monies have been or shall, directly or indirectly, be paid or offered by it or on its behalf to
any Government Authority (as defined below), or to any Government Officials (as defined below), for the purpose of improperly obtaining,
retaining or directing any business opportunity related to this Agreement.

 

For the purpose of this Section
13.2(c) –

 

		(i)	“Government” or “Government Authority” means any governmental
agency or instrumentality, government owned or controlled entity such as a state-owned or controlled company, political Party,
and/or public international organization; and
	 	 	 

		(ii)	“Government Officials” means any representatives, officers and/or employees
of any of the aforementioned entities mentioned in the definition of “Government”, including (without limitation) a
candidate of a political Party.

 

In addition, the Distributor hereby
represents and warrants that (i) it is not beneficially owned or controlled, directly or indirectly, by any Government Authority
or Government Official; (ii) that there are no actual or threatened legal proceedings and/or investigations of any Government Authority,
judicial or other competent authority against the Distributor, whether within the Territory or outside its borders; and (iii) that
there is no family relationship between the Distributor and Government Officials.

 

Any breach by Distributor of any
undertaking in this Section 13.2(c) shall be deemed a material breach of this Agreement and any contract or business relationship
between Distributor and G MEDICAL, and, notwithstanding anything to the contrary contained in Section 16 below, shall entitle G
MEDICAL to terminate this Agreement and any such other contract or business relationship immediately. Such right of termination
for breach shall be in addition and without prejudice to any other rights and remedies which G MEDICAL may have in contract and/or
at law with respect to such breach.

 

14. INTELLECTUAL PROPERTY

 

The Distributor hereby acknowledges and
agrees that all right, title, and interest in and to, G MEDICAL’s Intellectual Property, are and shall remain the sole and
exclusive property of G MEDICAL. Distributor is granted no title or ownership rights in or to G MEDICAL’s Intellectual Property.

 

    		Page 8 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Without derogating from the above, G MEDICAL
reserves all proprietary rights in and to (i) all designs, engineering details and other data pertaining to the Products, (ii)
all original works, computer programs, discoveries, inventions, patents, know-how, and techniques arising out of, and/or (iii)
any and all products or services developed as a result of, the Products.

 

For the purposes of this Agreement:

 

“Intellectual Property”
means all intellectual, moral, industrial and/or proprietary property and rights now or hereafter recognized under any applicable
law or in equity anywhere in the world, whether issued or pending, registered or unregistered, including, but not limited to (i)
all forms of patents and utility models; (ii) inventions, discoveries, (whether patentable or not); (iii) rights associated with
works of authorship, including but not limited to copyrights and maskworks; (iv) trademarks and service marks, trade names, domain
name registration; (v) designs (whether or not capable of registration), design rights; (vi) database rights; (vii) trade secrets
and know how; (viii) all rights to confidential or proprietary information; and with respect to the intellectual property included
in paragraphs (i) to and including (viii) above - any rights analogous to those mentioned herein; all derivative works thereof;
and any current or future applications, renewals, extensions, restorations, provisionals, continuations, continuations-in-part,
divisions, reexaminations and reissues thereof; the right to apply to any of the above; and all of the tangible embodiments thereof.

 

“Intellectual Property Rights”
means all rights, title and interest in and to any Intellectual Property.

 

14.1 All rights not expressly granted to
Distributor in this Agreement are retained by G MEDICAL. Section 1.2 above sets out Distributor’s sole right with respect
to the Products.

 

In no event shall Distributor have any
other right with respect to the Products, including, without limitation, a right, permission or license to use the same or any
part thereof for any purpose whatsoever.

 

The Distributor acknowledges and agrees
that it neither possesses nor will seek any rights in G MEDICAL’s Intellectual Property.

 

14.2 Any goodwill associated with or created
with respect to the Products and the Marks in the Territory or elsewhere as a result of the Distributor’s performance of
this Agreement, shall be owned solely by G MEDICAL, and Distributor hereby irrevocably waives any demand or claim in this respect.
Without limiting the generality of the above, the Distributor hereby irrevocably and unconditionally assigns to G MEDICAL (and/or
such other third party as shall be instructed by G MEDICAL) all goodwill in and to the Products and the Marks created in connection
with the performance of the Distributor’s obligations hereunder.

 

14.3 Distributor shall promptly notify
G MEDICAL in writing of any infringement or other violation of G MEDICAL’s Intellectual Property Rights to which Distributor
becomes aware.

 

G MEDICAL shall have the sole and exclusive
right to protect and defend G MEDICAL’s Intellectual Property Rights, at its sole cost and expense. Distributor shall reasonably
cooperate with G MEDICAL, at G MEDICAL’s expense, in the defense and protection of such Intellectual Property Rights.

 

15. CONFIDENTIAL
INFORMATION

 

15.1 G MEDICAL
and Distributor acknowledge that certain non-public, proprietary, or confidential information of each Party may be disclosed to
the other Party in connection with this Agreement. Each Party receiving such non-public, proprietary, or confidential information
(the “Receiving Party”) agrees that it will take steps at least substantially equivalent to the steps it takes
to protect its own non-public, proprietary, or confidential information (but in no event less than reasonable care), during the
term of this Agreement and for a period of there (3) years following expiration or termination of this Agreement, to retain
in confidence the terms of this Agreement and all other non-public, proprietary or confidential information, technology, materials
and know-how of the other Party disclosed or acquired by the Receiving Party pursuant to or in connection with this Agreement(“Confidential
Information”).

 

    		Page 9 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

15.2 Except as permitted herein, each Party
agrees to hold in confidence, not to disclose, to prevent the disclosure of Confidential Information of the other Party and to
refrain from copying, distributing, disseminating or otherwise disclosing such Confidential Information to, any third party; provided
that each Party may disclose Confidential Information to its directors, officers, employees advisors or agents who (i) need to
have access to such Confidential Information for such Party to perform its obligations hereunder and (ii) will agree to treat Confidential
Information in the same manner and to the same extent as is required of the Receiving Party hereunder. The provisions of this Section
15.2 above shall not relieve the Receiving Party from its obligations hereunder, and any breach of this Agreement by Receiving
Party’s directors, officers, etc., shall be deemed as a breach of this Agreement by Receiving Party. Each Party shall notify
the other Party promptly in writing in the event such Party learns of any actual or suspected unauthorized use or disclosure of
any Confidential Information that it has received from the other Party, and will cooperate in good faith to remedy such unauthorized
use or disclosure to the extent reasonably possible.

 

15.3 The Receiving Party undertakes not
to use the Confidential Information of the Disclosing Party for any purposes other than for the purposes of performing this Agreement,
and not to sell, grant, make available to, or otherwise allow the use of the Disclosing Party’s Confidential Information
by any third party, directly or indirectly, except as expressly permitted herein.

 

15.4 Without derogating from the generality
of the above, Distributor undertakes not to use, directly or indirectly, the Confidential Information of G MEDICAL in the development
and/or sale of products having the same or similar functions as the Products, for itself or for a third party.

 

15.5 All Confidential Information shall
be and remain the property of the Disclosing Party. Disclosure of the Disclosing Party’s Confidential Information to the
Receiving Party shall not be construed as granting the Receiving Party any right, title, or license, whether express or implied,
with respect to the Confidential Information or to its related Intellectual Property or products (including, but not limited to,
improvements, modifications and/or derivatives related to the Confidential Information), other than the right to use the Confidential
Information strictly in accordance with the provisions of this Agreement and the relevant Purchase Order. The right to file property
rights based on the Confidential Information shall be reserved to the Disclosing Party. The Receiving Party shall not assert a
right based on prior use, or assert an objection of public prior use, against property rights based on Confidential Information
received under this Agreement.

 

15.6 The restrictions hereunder with respect
to Confidential Information shall not apply to any information that: (i) was known by the Receiving Party without obligation of
confidentiality prior to disclosure thereof by the other Party due to no wrong doing of the Receiving Party, as can be substantiated
by written and dated records; (ii) was in or entered the public domain through no breach by the Receiving Party of its obligation
with respect to Confidential Information; (iii) is disclosed to the Receiving Party by a third party legally entitled to make
such disclosure without violation of any obligation of confidentiality; (iv) is independently developed by the Receiving Party
without use or reference to any Confidential Information of the other Party, as can be substantiated by written and dated records;
or (v) is expressly released in writing from such obligations by the Disclosing Party.

 

15.7 Disclosing Party’s Confidential
Information is provided on an “as is” basis, with no warranty, express or implied, regarding the accuracy and/or
completeness thereof.

 

Upon (I) the written request of the Disclosing
Party, or (ii) expiration or termination for any reason of this Agreement or the applicable Purchase Order (to the extent related
to the Confidential Information), the Receiving Party shall return to the other or destroy (as requested by the Disclosing Party
at its sole discretion), all materials, in any medium, which contain or reveal all or any part of any Confidential Information
of the Disclosing Party. The Receiving Party shall confirm such destruction or return in writing to the Disclosing Party.

 

    		Page 10 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Each Party
acknowledges that breach of its obligation with respect to Confidential Information as provided by this Section 15 may result in
extensive and irreparable harm and damage to the other Party, for which money damages would be an insufficient remedy, and therefore
the non-breaching Party shall be entitled to seek injunctive relief to enforce the provisions of this Agreement with respect to
Confidential Information, in addition to any other remedy available to the other Party under applicable law. In such event, the
Party seeking injunctive relief to prevent use or disclosure of its Confidential Information as above, shall not be bound by the
escalation procedure set out in Section 16.16 below

 

15.8 Notwithstanding
anything to the contrary contained elsewhere in this Agreement, either Party may issue a disclosure containing Confidential Information
of the other Party without the consent of the other Party to the extent such disclosure is required by law, rule, regulation, judicial
or administrative order, or government or court order or evidenced by a subpoena, or is requested by a governmental or other entity
authorized by law to make such request (including, without limitation, a stock exchange where Receiving Party's stocks are listed
for public trading); provided, however, that, to the extent reasonably practicable, the disclosing Party will provide prompt prior
written notice to the other Party and will reasonably cooperate with the other Party (at the Disclosing Party's expense), if it
seeks a protective order or takes other legal action to prevent the disclosure of such Confidential Information (unless the disclosing
Party is prohibited by law from so doing), and, provided further, that the disclosure shall be limited to the extent expressly
required.

 

15.9 The
provisions of this Section 15 shall survive any expiration or termination of this Agreement and shall remain in effect and binding
upon the Parties following the date of such expiration or termination, as the case may be.

 

 16. GENERAL PROVISIONS

 

16.1 Notices.
Any and all notices which either Party may desire to give the other Party must be in writing and may be given by (i) personal delivery
to an officer of the Party, (ii) by mailing the same by registered or certified mail, postage prepaid, return receipt requested,
or via internationally recognized courier services to the Party at the address of such Party as set forth in the heading of this
Agreement, or such other address as the Parties may hereinafter designate. Such notice or other communications shall be deemed
to have been given on the date confirmed as the actual date of delivery by the courier service if sent by such service.

 

16.2 Governing Law and
Jurisdiction. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be
governed, construed and interpreted in accordance with the laws of England and Wales ,
exclusive of conflict or choice of law rules. This Agreement shall not be governed by the United Nations Convention on the
International Sale of Goods. G MEDICAL and Distributor will attempt to settle any claim or controversy arising out of this
Agreement through consultation and negotiation in good faith and spirit of mutual cooperation. Disputes will be resolved by
the following process. The dispute will be submitted in writing to a panel of two (2) senior executives, one from each of G
MEDICAL and Distributor for resolution. If the executives are unable to resolve the dispute within fifteen (15) days, either
Party may refer the dispute to mediation, the cost of which will be shared equally by the Parties, except that each Party
will pay its own attorney's fees. Within fifteen (15) days after written notice demanding mediation, the Parties will choose
a mutually acceptable mediator. Neither Party will unreasonably withhold consent to the selection of the mediator. Mediation
shall be conducted in London, England (UK) . If the dispute cannot be resolved through mediation within forty-five (45) days,
either Party may submit the dispute to arbitration pursuant to the Commercial Arbitration Rules of the UK Arbitration
Association. All proceedings shall take place before a single arbitrator in London City.

 

16.3 Compliance.
Each Party agrees to and shall comply with all applicable provincial, federal, and where applicable, local rules

and regulations.

 

    		Page 11 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

16.4
Indemnification. Distributor will indemnify, defend and hold harmless G MEDICAL, and its officers, directors, employees
and agents thereof (hereinafter referred to as the "G MEDICAL Indemnitees") from and against any and all claims,
demands, suits, actions, liabilities, judgments, losses, deficiencies, damages and expenses (including reasonable attorneys’
fees), incurred in investigating and defending against any claims, actions or liabilities asserted against or suffered by G MEDICAL
and/or G MEDICAL's Indemnitees arising out of or in connection with (i) any services and related activities by Distributor or
its employees or agents pursuant to this Agreement; (ii) the violation by Distributor of any of the obligations under this Agreement
or under any applicable law, rule or regulation, or (iii) any of Distributor's representations in Section 13 above being inaccurate
or false. G MEDICAL shall give prompt written notice to Distributor after learning of any such claim, action or liability for
which indemnification is provided herein, but the failure to give such notice shall not release Distributor from its indemnification
obligations hereunder.

 

16.5 LIMITATION
OF LIABILITY. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL G MEDICAL BE LIABLE TO THE DISTRIBUTOR OR
ANY THIRD PARTY FOR (I) ANY INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, (II) ANY DAMAGES RESULTING FROM LOSS
OF REVENUES, LOSS OF PROFITS, LOSS OF GOODWILL OR LOSS OF USE, AND/OR (III) ANY THIRD PARTY CLAIMS AGAINST DISTRIBUTOR; ARISING
OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT AND/OR ANY PRODUCTS OR PURCHASE ORDER, REGARDLESS OF THE BASIS FOR LIABILITY OF ANY
CLAIM (BE IT CONTRACT, TORT, OR OTHERWISE), EVEN IF G MEDICAL WAS INFORMED OF THE POSSIBILITY OF SUCH DAMAGES.

 

G MEDICAL’S MAXIMUM CUMULATIVE
LIABILITY TO DISTRIBUTOR UNDER THIS AGREEMENT AND/OR ANY PURCHASE ORDER, SHALL NOT EXCEED THE AMOUNT RECEIVED BY G MEDICAL FROM
DISTRIBUTOR FOR THE APPLICABLE PURCHASE ORDER THAT IS THE SUBJECT OF THE DISPUTE.

 

THE ABOVE LIMITATIONS OF LIABILITY
SHALL ALSO APPLY TO THE BENEFIT OF G MEDICAL’S DIRECTORS, EMPLOYEES, AGENTS AND SUBCONTRACTORS.

 

16.6
Insurance. Distributor shall maintain products liability and such other insurance coverage as G MEDICAL
may reasonably require from time to time containing such terms and policy limits as G MEDICAL may reasonably require. Upon request,
Distributor shall deliver a certificate of insurance demonstrating existent coverage.

 

16.7 Export.
Distributor agrees to comply with the applicable export and import control laws, regulations and requirements in all countries
where Distributor shall resell the Products, and G MEDICAL assumes no responsibility or liability for Distributor's failure to
obtain any such necessary export and import approvals.

 

Without derogating form the generality
of the above, Distributor agrees to comply with all applicable laws and regulations which may govern the export of the Products,
including without limitation, the Export Administration Act of 1979, as amended, any successor legislation and the Export Administration
Regulations issued by the Department of Commerce. Distributor hereby gives its assurance that neither Products, parts, software,
or technical data provided by G MEDICAL under this Agreement are intended to be shipped, directly or indirectly, to prohibited
countries or nationals thereof.

 

16.8 Media
Releases. Except for any announcement intended solely for internal distribution or any disclosure required by legal, accounting,
or regulatory requirements, all media releases, public announcements, or public disclosures, including but not limited to promotional
or marketing material, by Distributor or its employees or agents relating to this Agreement or its subject matter, or including
the Marks of G MEDICAL, shall be coordinated with and approved in writing by G MEDICAL prior to the release thereof.

 

16.9 Section
Headings. Section headings in this Agreement are for convenience only, and shall not be used in construing the Agreement.

 

16.10 Incorporation
of all Exhibits. Each Exhibit (as defined below) referred to and attached hereto is incorporated by reference as if set forth
fully herein.

 

    		Page 12 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

16.11 Severability.
If any provision of these terms and conditions shall be held to be invalid, illegal or unenforceable, such provision shall be enforced
to the fullest extent permitted by applicable law and the validity, legality and enforceability of the remaining provisions shall
not in any way be affected or impaired thereby.

 

16.12 No
Implied Waivers. If either Party fails to require performance of any duty hereunder by the other Party, such failure shall
not affect its right to require performance of that or any other duty thereafter. The waiver by either Party of a breach of any
provision of this Agreement shall not be a waiver of the provision itself or a waiver of any breach thereafter, or a waiver of
any other provision herein.

 

16.13 Amendment.
This Agreement shall not be amended without the express prior written consent of both Parties hereto. Any amendment affected in
accordance with this Section 16.13 shall be binding upon all Parties hereto.

 

16.14 Assignment.
None of Distributor’s rights created nor obligations imposed hereunder or under and Purchase Order shall be assigned, subcontracted
or otherwise transferred to any other person or company, whether by operation of law or otherwise without G MEDICAL’s prior
written approval. Any purported assignment without such prior written approval shall be null and void, shall not be binding upon
G MEDICAL and shall not relieve Distributor from any liability or obligation under this Agreement. Subject to the foregoing, this
Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted
assigns.

 

16.15 Entirety.
This Agreement, together with its Exhibits, constitutes the entire agreement between the Parties regarding its subject matter.
This Agreement supersedes any and all previous proposals, representations or statements, oral or written. Any previous agreements
between the Parties pertaining to the subject matter of this Agreement are expressly terminated. Any modifications or amendments
to this Agreement must be in writing and signed by authorized representatives of both Parties. In the event of any inconsistency
or contradiction between the provisions of this Agreement and the provisions of an Exhibit or a Purchase Order, the provisions
of this Agreement will prevail with respect to the subject matter of such inconsistency or discrepancy.

 

16.16 Force
Majeure. A Party hereto shall not be liable for any delay, loss and/or damage resulting from causes beyond the control thereof,
including, but not limited to, acts of God, acts of a public enemy, acts of any governmental or quasi-governmental agency or any
of their political subdivisions, fire, flood, epidemics, explosion, power or telecommunications irregularities, quarantine restrictions;
strikes or other labor unrest, earthquakes, civil commotion or revolutions, war, terrorist attack, freight embargoes, unusually
severe weather conditions, or any other cause that was not reasonably foreseeable by such Party on the date of signing of this
Agreement or the relevant Purchase Order.

 

16.17 No
Solicitation. During the term of this Agreement and for a period of six (6) months from the expiration or termination thereof
for any reason, neither Party shall (i) solicit to hire or otherwise employ any of the executive officers, technical personnel
and/or other employees of the other Party or of the other Party's subcontractors, except by the prior written consent of the other
Party, nor (ii) solicit suppliers and/or customers of the other Party to cease their cooperation therewith. Solely for purposes
of this Section 16.19, the other Party's independent contractors shall be deemed as such Party's employees.

 

16.18 No
Third Party Beneficiaries. This Agreement does not create any obligation of a Party to any third parties, nor shall it be deemed
to create any rights or causes of action on behalf of any third parties.

 

16.19 Remedies.
All remedies, either under this Agreement or by law otherwise affording to any Party, shall be cumulative and not alternative

 

16.20 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which will be considered an original, but all of which
together will constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by facsimile or electronic transmission shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

 

16.21 Language.
The Parties hereto have requested that this Agreement and all correspondence and all documentation relating to

this Agreement,
be written in the English language.

 

[remainder of page intentionally
left blank; signature page follows]

 

    		Page 13 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

IN WITNESS WHEREOF, G MEDICAL
and Distributor have caused this Agreement to be executed by their duly authorized representatives, each of which shall constitute
an original as of the Effective Date.

  

	 	 	 
	G Medical Innovations Ltd	 	 

  

	By:	/s/ Brendan de
    Kauwe	 	By:	/s/ Graham Russell
	Printed Name:  Brendan
    de Kauwe	 	Printed Name:  Graham Russell
	Title:	Director	 	Title:	Managing Director
	Date:	21/4/20	 	Date:	22 April 2020

 

	 	By:	/s/ Melanie Ross
	 	Printed Name: Melanie Ross              
	 	Title: 	 Company Secretary
	 	Date:	 22 April 2020

   

    		Page 14 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT A

 

PRODUCTS and PRODUCT TERMS

 

		1.	PRODUCTS

 

		a.	Product 1

 

		·	Prizma G2 with User portal

 

		1.	API for transfer data to Australian third-party cloud.
	 	 	 

		2.	Launching of Prizma APP from another HSC application.
	 	 	 

		3.	Integration of Prizma APP into HSC portal

 

    		Page 15 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT B

 

TERRITORIES

 

Distributor may resell and distribute the Products
only in:

 

		1.	Australia (non-exclusive)

 

		2.	New Zealand (non-exclusive)

 

    		Page 16 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT C

 

PRODUCT FORECAST & PRICE LIST

 

FORECAST (MOQ) – in accordance to para
3.1. :

 

PRIZMA:

 

		1.	20 units (Prizma G2) initial order, thereafter units may
be ordered as required.

 

PRICE LIST:

 

PRIZMA:

 

		1.	Distributor price: $150 per unit (Prizma G2).
	 	 	 

		2.	Retail (consumer) Price: $249.
	 	 	 

		3.	Prizma Portal fee of no less than $9 per month.
	 	 	 

		(a)	Portal fee of 30% payable to Distributor.
	 	 	 

		(b)	Additional service fees to be agreed between G Medical
and Distributor.

 

 

    		Page 17 of 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]